Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Apollo Endosurgery, Inc. to Participate at the 30th Annual ROTH Conference

Apollo Endosurgery,Inc.
Posted on: 05 Mar 18

Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that Company management is scheduled to present at the 30th Annual ROTH Conference being held March 11-14, 2018 at the Ritz-Carlton Laguna Niguel in Orange County, CA. The presentation is scheduled for Monday, March 12, 2018 at 11:00 am PT.

Investors attending the conference who would like to schedule a one-on-one meeting with Apollo management may do so by contacting their ROTH Capital Partners representative, or Lee Roth of The Ruth Group at

An audio webcast of the Company’s presentation will be available online at A replay of the presentation will be available for 90 days.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today.

Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN." For more information regarding Apollo Endosurgery, go to:

View source version on

Business Wire

Last updated on: 05/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.